Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05776017
Other study ID # V4ALL/MSP3/009
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 27, 2023
Est. completion date August 31, 2024

Study information

Verified date April 2023
Source Vac4All
Contact Zarifah H Reed, MD, MPH
Phone +33695695786
Email zahussain22@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Two-arm, randomized, double-blinded and controlled clinical trial to first assess the safety and tolerability of the vaccine in a Phase 1b trial and proceed to assess its efficacy against clinical malaria in young children living in highly seasonal malaria areas of Mali


Description:

This study is designed to be executed in two steps to achieve the primary efficacy objective: The first step is a Phase 1b safety study, involving injections in a small safety subgroup for each dose before age-de-escalation into the younger age group and then proceeding to the second step of dosing the corresponding injection in the larger Phase 2b efficacy cohort. Vaccination of the Phase 2b cohort will require an acceptable reactogenicity data over the first week following the corresponding vaccination of the older and younger age groups in the Phase 1 subgroup. The study DSMB will be charged with this review and ensuring that vaccination proceeds only if the reactogenicity profile meet study "go" criteria (Table 1). The objectives of each phase are: Phase 1b: The primary objective is to assess the safety and tolerability of the vaccine for each injection. The secondary objective is to evaluate the immune response to the vaccine and safety for up to 12 months after the first dose. Phase 2b: The primary objective is to assess the efficacy in young children* against clinical malaria** during one transmission season. The timeline for the primary analysis assessment is from 14 days to 6 months after Dose 3. Should the primary analysis data demonstrate that the vaccine gives good efficacy, a boost vaccination will be programmed to be administered to willing subjects before the start of the subsequent transmission season. The study protocol will be amended with the precise details in this event.


Recruitment information / eligibility

Status Recruiting
Enrollment 465
Est. completion date August 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 59 Months
Eligibility Inclusion Criteria: - Children aged 12-59 months years old - Healthy by medical history, physical examination and laboratory investigation - Signed/thumb printed informed Consent by guardian/parent - Resident in the study area villages during the whole trial period Exclusion Criteria: - Symptoms, physical signs of disease that could interfere with the interpretation of the trial results or compromising the health of the participants - Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within 3 months prior recruitment. (For corticosteroids, this will mean prednisone, or equivalent, more or equal to 0.5 mg/kg/day. Inhaled and topical steroids are allowed.) - Cannot be followed for any social, psychological or geographical reasons. - Use of any investigational drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to 30 days after the third dose. - Suspected or known hypersensitivity to any of the vaccine components or to previous vaccine. - Clinically significant laboratory abnormalities on screened blood samples. - Planned administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. An exception, is the receipt of an childhood immunization program or licensed vaccine (measles, oral polio, Hib, meningococcal and combined diphtheria/pertussis/tetanus vaccines) which may be given before or after vaccination*. - Evidence of chronic or active hepatitis B or C infection - Presence of chronic illness that, in the judgment of the investigator, would interfere with the study outcomes or pose a threat to the participant's health. - Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period - History of surgical splenectomy. - Moderate or severe malnutrition at screening based on clinical judgement. o (Weight-for-age Z score of less than -3 or other clinical signs of malnutrition). - Previous participation to a malaria vaccine trial - Known history of HIV infection

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
MSP3-CRM-Vac4All/ Alhydrogel®
30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant
Anti-Rabies Vaccine
Control vaccine

Locations

Country Name City State
Mali Malaria Research and Training Center (MRTC), University of Sciences Techniques and Technologies of Bamako, Mali Bamako

Sponsors (2)

Lead Sponsor Collaborator
Vac4All Malaria Research and Training Center, Bamako, Mali

Country where clinical trial is conducted

Mali, 

Outcome

Type Measure Description Time frame Safety issue
Primary Protective Efficacy against Clinical Malaria To assess the efficacy of 30 µg MSP3-CRM-Vac4All/Alhydrogel® vaccine in children ages 12-60 months old, against clinical malaria occurring over one transmission season.
The primary efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL
The timeline for assessment will be from 14 days to 6 months after Dose 3.
Secondary Efficacy- different definitions of malaria fever and parasite thresholds on microscopy To compare efficacy against clinical malaria for different case definitions using
Fever thresholds that are higher than 37.5ºC, such as 38.5ºC and 39.5ºC
History of fever instead of measured fever
Different parasitemia by microscopy thresholds [any parasitemia, 1000, 10,000 and 20,000/µL]
Efficacy outcomes
clinical malaria episodes defined as a febrile episode with an axillary temperature of = 38.5ºC with P. falciparum parasitemia =5000/µL or = 39.5ºC with P. falciparum parasitemia =5000/µL or
clinical malaria episodes defined as history of fever with P. falciparum parasitemia of the following levels: any parasitemia, 1000, 10,000 and 20,000/µL clinical malaria episodes defined as a febrile episode with an axillary temperature of = 38.5ºC with or = 39.5ºC with P. falciparum parasitemia of the following levels: any parasitemia, 1000, 10,000 and 20,000/µL
For 12 months after first vaccination
Secondary Efficacy duration To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against clinical malaria occurring during the 12 months following dose 3. For 12 months following the first vaccination
Secondary Efficacy against first malaria episodes To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against first clinical malaria episodes occurring from over the 6 month period 14 days after 2nd and 3rd vaccination and up to the end of study follow-up (12 months after first vaccination).
The efficacy outcome is first episode of clinical malaria, with the case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL
From 14 days post 2nd or 3rd vaccination to 6 months following and up to the end of study follow-up (12 months after first vaccination
Secondary Efficacy (conditional boost) To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against clinical malaria occurring The efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL For the 6 months following boost vaccination
Secondary Efficacy (conditional boost) To assess the efficacy of MSP3-CRM-Vac4All/Alhydrogel® in young children against clinical malaria occurring.
The efficacy outcome is clinical malaria, with the primary case definition of clinical malaria episodes defined as a febrile episode with an axillary temperature of = 37.5ºC with P. falciparum parasitemia =5000/µL
For the 12 months following boost vaccination
Secondary Number of adverse events To assess the safety and reactogenicity of 3 doses of 30 µg MSP3-CRM-Vac4All/Alhydrogel® given at D0, D28 and D56 in healthy young children During the month following each vaccination, and 6 months and 12 months after first vaccination.
Secondary Number of adverse events for conditional boost vaccination Safety and reactogenicity of boost vaccination doses of MSP3-CRM-Vac4All/Alhydrogel® in healthy young children At one month, 6 month and 12 months following boost vaccination
Secondary Immune response To examine the duration of immune responses of a 3-dose regimen of during periods corresponding to that used for primary and other secondary efficacy endpoints as measured through a > 5-fold decrease of MSP3-specific serum IgG antibody titers after each vaccination in comparison to baseline levels (14 days post last dose) From 14 days post last dose to up to a month after last dose, 6 months after last dose and 12 months after first dose
Secondary Immune response To determine immunogenicity in terms of the proportion with titres either more than 3SD above the median for negative controls (positive) or at least 50% of the positive controls (strongly positive) after dose 3. A month after dose 3
Secondary Parasite densities To measure effect on parasitemia by comparing parasite densities in malaria episodes occurring in vaccinees compared to control From vaccination to up to 6 months after last dose and 12 months after first dose.
See also
  Status Clinical Trial Phase
Terminated NCT04130282 - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Phase 1
Completed NCT04049916 - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Phase 2/Phase 3
Active, not recruiting NCT03814616 - Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections Phase 2
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT05135273 - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali Phase 1
Not yet recruiting NCT06083688 - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Phase 4
Recruiting NCT03511443 - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections N/A
Completed NCT05550909 - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Phase 2
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed NCT05081089 - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali Phase 2
Recruiting NCT05150808 - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania Phase 3
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Completed NCT01992900 - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria Phase 2
Completed NCT04565184 - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde Phase 4
Completed NCT03896724 - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso Phase 1/Phase 2
Completed NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 N/A
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Completed NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Recruiting NCT04271306 - Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.